InClinica CEO Speaks at The 2nd Wound Care: From Innovations to Clinical Trials Conference in the United Kingdom
James Nolan discussed global clinical trial strategy in Edinburgh
PHILADELPHIA (June 13, 2018) – InClinica, a global, clinical CRO, announced that CEO James Nolan spoke at The 2nd Wound Care: From Innovations to Clinical Trials (WCICT2018) conference on June 13, 2018, in Edinburgh, U.K.
Nolan’s lecture, titled “Clinical Trial Strategy: What it Takes to Compete,” addressed how companies can compete in the clinical trial sphere through effective strategies. He also offered guidance on how to position products and successfully access the global market.
“With an increase in clinical trials worldwide, a strong focus on company strategy is more crucial than ever,” said Nolan. “From overall company strategy assessment to a focus on drug labeling, understanding the global clinical trial landscape is key when it comes to leveraging a new product and recruiting patients.”
The 2nd Wound Care: From Innovations to Clinical Trials conference in the U.K. presents updates in various areas of the clinical research industry. Topics include clinical trials in wound prevention and care, risk assessment and management, novel approaches to wound prevention and care, cost effectiveness of interventions, infection prevention and management and treatment of burns. For more information, visit: http://www.wcict2018.com/default.aspx.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.